PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337607
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337607
Virtual Clinical Trials Market Size and Share Report by Type, Indication, Phase - Global Industry Demand Forecast to 2030
The size of the virtual clinical trials market will power at a compound annual growth rate of 5.9% during 2022-2030, to touch a value of USD 12,987.4 million by 2030.
This is due to rising rate of digitization in the healthcare industry, surging clinical research activities, and the increasing demand for new vaccines and treatments and technologies that allow clinical trials to be conducted online.
The market is going through clinical trial platforms and technological developments in patient recruitment which have made it possible to analyse trial data effectively.
In a fully decentralised or virtual approach, patient recruitment, intervention delivery, and outcome data collection can all be completed without the patients' actual physical presence.
Virtual clinical trials are a revolutionary method that allows participants to take part in the study from the comfort of their own homes without travelling to the study site. Additionally, this aids in maintaining effective control over the gathering of participant data for clinical trials.
Clinical trials have become more patient-centric due to decentralised technologies, which have also revolutionised product development. As a result, market participants are working on a variety of strategic initiatives to provide the finest services and to reduce trial costs.
The interventional category maintained the greatest share, around 50% due to the increased number of research and development efforts focused on innovative medicines and digitization at the laboratory level.
Experimental research also known as interventional studies, enables the medical community to determine the cause-and-effect between an intervention or treatment. When doing epidemiological research on preventative or therapeutic products, such studies provide trustworthy evidence.
Decentralised platforms, tools, and solutions are anticipated to gain more focus as a result of strong government support and severe clinical trial laws in the United States. Additionally, governments in a number of poor nations are launching measures to increase the quantity of clinical studies.
Due to the presence of many significant market players, North America held a 40% share of the global virtual clinical trials market. The market is also fuelled by expanding R&D spending, the use of new technologies in clinical research, and government funding for pharmaceutical research.
For instance, from 19.1% in 2021 to 20.7%, the rate of new research project grant success grew by 1.6%. Additionally, the NIH spent over USD 43 billion on research to lessen the burden of disease.
Furthermore, the U.S. accounts for the biggest share-more than 31%-of all clinical studies reported globally. Additionally, this nation accounts for more than 32% of all patient recruiting for similar research worldwide.
Traditional clinical trial methods are becoming obsolete due to the rising number of registrations; hence the virtual method is expected to be used most in the upcoming years and this will lead to market growth.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by indication
- 1.4.3. Market size breakdown, by phase
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Industry Outlook
- 6.1. Market Dynamics
- 6.1.1. Trends
- 6.1.2. Drivers
- 6.1.3. Restraints/challenges
- 6.1.4. Impact analysis of drivers/restraints
- 6.2. Impact of COVID-19
- 6.3. Porter's Five Forces Analysis
- 6.3.1. Bargaining power of buyers
- 6.3.2. Bargaining power of suppliers
- 6.3.3. Threat of new entrants
- 6.3.4. Intensity of rivalry
- 6.3.5. Threat of substitutes
Chapter 7. Global Market
- 7.1. Overview
- 7.2. Market Revenue, by Type (2017-2030)
- 7.3. Market Revenue, by Indication (2017-2030)
- 7.4. Market Revenue, by Phase (2017-2030)
- 7.5. Market Revenue, by Region (2017-2030)
Chapter 8. North America Market
- 8.1. Overview
- 8.2. Market Revenue, by Type (2017-2030)
- 8.3. Market Revenue, by Indication (2017-2030)
- 8.4. Market Revenue, by Phase (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. Europe Market
- 9.1. Overview
- 9.2. Market Revenue, by Type (2017-2030)
- 9.3. Market Revenue, by Indication (2017-2030)
- 9.4. Market Revenue, by Phase (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. APAC Market
- 10.1. Overview
- 10.2. Market Revenue, by Type (2017-2030)
- 10.3. Market Revenue, by Indication (2017-2030)
- 10.4. Market Revenue, by Phase (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. LATAM Market
- 11.1. Overview
- 11.2. Market Revenue, by Type (2017-2030)
- 11.3. Market Revenue, by Indication (2017-2030)
- 11.4. Market Revenue, by Phase (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. MEA Market
- 12.1. Overview
- 12.2. Market Revenue, by Type (2017-2030)
- 12.3. Market Revenue, by Indication (2017-2030)
- 12.4. Market Revenue, by Phase (2017-2030)
- 12.5. Market Revenue, by Country (2017-2030)
Chapter 13. U.S. Market
- 13.1. Overview
- 13.2. Market Revenue, by Type (2017-2030)
- 13.3. Market Revenue, by Indication (2017-2030)
- 13.4. Market Revenue, by Phase (2017-2030)
Chapter 14. Canada Market
- 14.1. Overview
- 14.2. Market Revenue, by Type (2017-2030)
- 14.3. Market Revenue, by Indication (2017-2030)
- 14.4. Market Revenue, by Phase (2017-2030)
Chapter 15. Germany Market
- 15.1. Overview
- 15.2. Market Revenue, by Type (2017-2030)
- 15.3. Market Revenue, by Indication (2017-2030)
- 15.4. Market Revenue, by Phase (2017-2030)
Chapter 16. France Market
- 16.1. Overview
- 16.2. Market Revenue, by Type (2017-2030)
- 16.3. Market Revenue, by Indication (2017-2030)
- 16.4. Market Revenue, by Phase (2017-2030)
Chapter 17. U.K. Market
- 17.1. Overview
- 17.2. Market Revenue, by Type (2017-2030)
- 17.3. Market Revenue, by Indication (2017-2030)
- 17.4. Market Revenue, by Phase (2017-2030)
Chapter 18. Italy Market
- 18.1. Overview
- 18.2. Market Revenue, by Type (2017-2030)
- 18.3. Market Revenue, by Indication (2017-2030)
- 18.4. Market Revenue, by Phase (2017-2030)
Chapter 19. Spain Market
- 19.1. Overview
- 19.2. Market Revenue, by Type (2017-2030)
- 19.3. Market Revenue, by Indication (2017-2030)
- 19.4. Market Revenue, by Phase (2017-2030)
Chapter 20. Japan Market
- 20.1. Overview
- 20.2. Market Revenue, by Type (2017-2030)
- 20.3. Market Revenue, by Indication (2017-2030)
- 20.4. Market Revenue, by Phase (2017-2030)
Chapter 21. China Market
- 21.1. Overview
- 21.2. Market Revenue, by Type (2017-2030)
- 21.3. Market Revenue, by Indication (2017-2030)
- 21.4. Market Revenue, by Phase (2017-2030)
Chapter 22. India Market
- 22.1. Overview
- 22.2. Market Revenue, by Type (2017-2030)
- 22.3. Market Revenue, by Indication (2017-2030)
- 22.4. Market Revenue, by Phase (2017-2030)
Chapter 23. Australia Market
- 23.1. Overview
- 23.2. Market Revenue, by Type (2017-2030)
- 23.3. Market Revenue, by Indication (2017-2030)
- 23.4. Market Revenue, by Phase (2017-2030)
Chapter 24. South Korea Market
- 24.1. Overview
- 24.2. Market Revenue, by Type (2017-2030)
- 24.3. Market Revenue, by Indication (2017-2030)
- 24.4. Market Revenue, by Phase (2017-2030)
Chapter 25. Brazil Market
- 25.1. Overview
- 25.2. Market Revenue, by Type (2017-2030)
- 25.3. Market Revenue, by Indication (2017-2030)
- 25.4. Market Revenue, by Phase (2017-2030)
Chapter 26. Mexico Market
- 26.1. Overview
- 26.2. Market Revenue, by Type (2017-2030)
- 26.3. Market Revenue, by Indication (2017-2030)
- 26.4. Market Revenue, by Phase (2017-2030)
Chapter 27. Saudi Arabia Market
- 27.1. Overview
- 27.2. Market Revenue, by Type (2017-2030)
- 27.3. Market Revenue, by Indication (2017-2030)
- 27.4. Market Revenue, by Phase (2017-2030)
Chapter 28. South Africa Market
- 28.1. Overview
- 28.2. Market Revenue, by Type (2017-2030)
- 28.3. Market Revenue, by Indication (2017-2030)
- 28.4. Market Revenue, by Phase (2017-2030)
Chapter 29. U.A.E. Market
- 29.1. Overview
- 29.2. Market Revenue, by Type (2017-2030)
- 29.3. Market Revenue, by Indication (2017-2030)
- 29.4. Market Revenue, by Phase (2017-2030)
Chapter 30. Competitive Landscape
- 30.1. List of Market Players and their Offerings
- 30.2. Competitive Benchmarking of Key Players
- 30.3. Product Benchmarking of Key Players
- 30.4. Recent Strategic Developments
Chapter 31. Company Profiles
- 31.1. Parexel International Corporation
- 31.1.1. Business overview
- 31.1.2. Product and service offerings
- 31.2. ICON plc
- 31.2.1. Business overview
- 31.2.2. Product and service offerings
- 31.2.3. Key financial summary
- 31.3. IQVIA Holdings Inc.
- 31.3.1. Business overview
- 31.3.2. Product and service offerings
- 31.3.3. Key financial summary
- 31.4. Dassault Systemes
- 31.4.1. Business overview
- 31.4.2. Product and service offerings
- 31.4.3. Key financial summary
- 31.5. Oracle Corporation
- 31.5.1. Business overview
- 31.5.2. Product and service offerings
- 31.5.3. Key financial summary
- 31.6. Signant Health
- 31.6.1. Business overview
- 31.6.2. Product and service offerings
- 31.7. Clinical Ink Inc.
- 31.7.1. Business overview
- 31.7.2. Product and service offerings
- 31.8. Medable Inc.
- 31.8.1. Business overview
- 31.8.2. Product and service offerings
- 31.9. Halo Health Systems
- 31.9.1. Business overview
- 31.9.2. Product and service offerings
- 31.10. Laboratory Corporation of America Holdings
- 31.10.1. Business overview
- 31.10.2. Product and service offerings
- 31.10.3. Key financial summary
- 31.11. CROPRIME Ltd.
- 31.11.1. Business overview
- 31.11.2. Product and service offerings
- 31.12. Medpace Holdings Inc.
- 31.12.1. Business overview
- 31.12.2. Product and service offerings
- 31.12.3. Key financial summary
- 31.13. WuXi AppTec
- 31.13.1. Business overview
- 31.13.2. Product and service offerings
- 31.13.3. Key financial summary
- 31.14. Syneos Health Inc.
- 31.14.1. Business overview
- 31.14.2. Product and service offerings
- 31.14.3. Key financial summary
- 31.15. Delve Health Inc.
- 31.15.1. Business overview
- 31.15.2. Product and service offerings
- 31.15.3. Key financial summary
Chapter 32. Appendix
- 32.1. Abbreviations
- 32.2. Sources and References
- 32.3. Related Reports
